OrbiMed Advisors co-led an oversubscribed series A financing of a new company creating RNA therapies for rare pulmonary diseases including cystic fibrosis.
ReCode Therapeutics announced an $80 million financing round also attracted interest from family office Colt Ventures, MPM Capital, Vida Ventures, Hunt Technology Ventures and Osage University Partners. The biopharmaceutical company is expecting to use the proceeds to continue its preclinical development program with plans to file its new drug application for its treatments for ciliary dyskinesia and cystic fibrosis in 2021.
“We believe that ReCode has an exceptional opportunity to advance its . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
